1,2-dipalmitoylphosphatidylcholine and Pulmonary Arterial Hypertension

1,2-dipalmitoylphosphatidylcholine has been researched along with Pulmonary Arterial Hypertension in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Han, X; Li, Z; Ma, M; Qiao, W; Tang, J; Wang, C; Wang, H	1

Other Studies

1 other study(ies) available for 1,2-dipalmitoylphosphatidylcholine and Pulmonary Arterial Hypertension

Article	Year
DPPC-coated lipid nanoparticles as an inhalable carrier for accumulation of resveratrol in the pulmonary vasculature, a new strategy for pulmonary arterial hypertension treatment. Drug delivery, 2020, Volume: 27, Issue:1 Topics: 1,2-Dipalmitoylphosphatidylcholine; Administration, Inhalation; Animals; Cell Proliferation; Cell Survival; Cells, Cultured; Drug Carriers; Drug Liberation; Drug Stability; Glycerides; Lung; Male; Myocytes, Smooth Muscle; Nanoparticles; Particle Size; Pulmonary Arterial Hypertension; Pulmonary Artery; Rats, Sprague-Dawley; Resveratrol; Surface Properties	2020

Article

Year

DPPC-coated lipid nanoparticles as an inhalable carrier for accumulation of resveratrol in the pulmonary vasculature, a new strategy for pulmonary arterial hypertension treatment.

Drug delivery, 2020, Volume: 27, Issue:1

Topics: 1,2-Dipalmitoylphosphatidylcholine; Administration, Inhalation; Animals; Cell Proliferation; Cell Survival; Cells, Cultured; Drug Carriers; Drug Liberation; Drug Stability; Glycerides; Lung; Male; Myocytes, Smooth Muscle; Nanoparticles; Particle Size; Pulmonary Arterial Hypertension; Pulmonary Artery; Rats, Sprague-Dawley; Resveratrol; Surface Properties

2020